Deep Brain Stimulation for the Treatment of Alzheimer's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2015 by Ohio State University
Information provided by (Responsible Party):
Ali Rezai, MD, The Ohio State University Identifier:
First received: March 19, 2012
Last updated: October 13, 2015
Last verified: October 2015
The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and functional disability of Alzheimer's disease.

Condition Intervention
Alzheimer's Disease
Device: Deep Brain Stimulation

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • Clinical Dementia Rating Scale [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: March 2012
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open Label
DBS Implant and stimulation
Device: Deep Brain Stimulation
Implanted device
Other Name: Deep Brain Stimulation Device


Ages Eligible for Study:   45 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria

Exclusion Criteria:

  • Has significant neurological disease, other than Alzheimer's disease, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas.
  • Evidence of substance abuse (alcohol or other drug) abuse or dependence during the previous 12 months (DSM-IV Criteria).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01559220

Contact: Phuong Nguyen, MBA, CCRP 614-366-6952
Contact: Jennifer Icenhour, CCRP 614-293-6882

United States, Ohio
Wexner Medical Center at the Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Phuong Nguyen    614-366-6952   
Principal Investigator: Ali Rezai, MD         
Sponsors and Collaborators
Ali Rezai, MD
Principal Investigator: Ali Rezai, MD Ohio State University
  More Information

No publications provided

Responsible Party: Ali Rezai, MD, MD, The Ohio State University Identifier: NCT01559220     History of Changes
Other Study ID Numbers: DBS for AD
Study First Received: March 19, 2012
Last Updated: October 13, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies processed this record on November 25, 2015